Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Positive Business Developments
August 12 2021 - 2:49PM
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW)
(“Adial” or the “Company”), a clinical-stage biopharmaceutical
company focused on developing therapies for the treatment and
prevention of addiction and related disorders, today announced it
will host a conference call at 11:00 A.M. Eastern Time on Friday,
August 20, 2021 to provide a clinical update and discuss the latest
business developments.
The conference call will be available via
telephone by dialing toll free 844-369-8770 for U.S. callers or +1
862-298-0840 for international callers. A webcast of the call may
be accessed at https://www.webcaster4.com/Webcast/Page/2463/42538
or on the Company’s website at https://ir.adialpharma.com/.
An audio replay of the call will be available
through September 3, 2021 and can be accessed by dialing
877-481-4010 for U.S callers or +1 919-882-2331 for international
callers and by entering the access code:
42538.
About Adial Pharmaceuticals,
Inc.
Adial Pharmaceuticals is a clinical-stage
biopharmaceutical company focused on the development of treatments
for addictions. The Company’s lead investigational new drug
product, AD04, is a genetically targeted, serotonin-3 receptor
antagonist, therapeutic agent for the treatment of Alcohol Use
Disorder (AUD) and is currently being investigated in the Company’s
landmark ONWARD™ pivotal Phase 3 clinical trial for the potential
treatment of AUD in subjects with certain target genotypes, which
are to be identified using the Company’s proprietary companion
diagnostic genetic test. A Phase 2b clinical trial of AD04 for the
treatment of AUD showed promising results in reducing frequency of
drinking, quantity of drinking and heavy drinking (all with
statistical significance), and no overt safety concerns (there were
no statistically significant serious adverse events reported). AD04
is also believed to have the potential to treat other addictive
disorders such as Opioid Use Disorder, gambling, and obesity. The
Company is also developing adenosine analogs for the treatment of
pain and other disorders. Additional information is available at
www.adialpharma.com.
Contact:Crescendo Communications,
LLC David
Waldman / Natalya
Rudman Tel:
212-671-1021 Email:
adil@crescendo-ir.com
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Apr 2023 to Apr 2024